Traditional approaches to drug discovery have focussed on making and testing large number of compounds in the laboratory. Inhibox, however, is based on using novel software to screen large libraries of molecules against therapeutic targets in order to predict which molecules are likely to be appropriate candidates for new drugs. This combination of screening software, very large compound libraries and computing power enables Inhibox to undertake a range of drug discovery services and collaborations. Inhibox is also undertaking a number of proprietary programmes.
|
As at 31 Dec 2012 |
IP Group holding |
IP Venture Fund* holding |
21.8% |
21.8% |
| |
*IP Group has a 10%
economic interest in IP
Venture Fund |
Holdings represent undiluted beneficial equity interest excluding debt